Generalized anxiety disorder (GAD) is a chronic anxiety disorder that leads to significant functional impairment and reduced quality of life. Pregabalin is a novel analogue of the inhibitory neurotransmitter gamma amino butyric acid, which has been proposed as a treatment for a range of conditions including GAD. This study examined the efficacy of pregabalin for GAD across published trials, using a meta-analytic method.
Method:
This study examined the 7 published placebo-controlled trials of GAD using pregabalin, and, using meta-analytic techniques, we calculated the effect size of treatment with pregabalin (compared with placebo) on a total of 1352 people.
Results:
The overall effect size of pregabalin in the treatment of GAD was Hedges' g = 0.364, with an effect size of 0.349 on psychic anxiety symptoms and of 0.239 on somatic anxiety symptoms.
Conclusion:
Pregabalin is an efficacious therapy for GAD, although effect sizes are smaller than those from earlier studies. Limitations and future research directions are discussed.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Arlington (VA): American Psychiatric Press; 2000.
2.
BarreraTLNortonPJ. Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord. 2009;23:1086–1090.
3.
SteinMBHeimbergRG. Well-being and life satisfaction in generalized anxiety disorder: Comparison to major depressive disorder in a community sample. J Affect Disord. 2004;79:161–166.
4.
KroenkeKSpitzerRLWilliamsJBAnxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146:317–325.
5.
JonesGNAmesSCJeffriesSKUtilization of medical services and quality of life among low-income patients with generalized anxiety disorder attending primary care clinics. Int J Psychiatry Med. 2001;21:183–198.
6.
SomersJMGoldnerEMWaraichPPrevalence and incidence of anxiety disorders: A systematic review of the literature. Can J Psychiatry. 2006;51:100–113.
BoschenMJNeumannDLWatersAM. Relapse of successfully treated anxiety and fear: Theoretical issues and recommendations for clinical practice. Aust N Z J Psychiatry. 2009;43:89–100.
9.
YonkersKABruceSEDyckIRChronicity, relapse, and illness—course of panic disorder, social phobia, and generalized anxiety disorder: Findings in men and women from 8 years of follow-up. Depress Anxiety. 2003;17:173–179.
10.
BaldwinDSAjelK.Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007;3:185–191.
11.
BoschenMJ. Generalized anxiety disorder in adults: Focus on pregabalin. CMI Psychiatry. 2011;4:17–35.
12.
BandelowDWedekindDLeonT.Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention. Expert Rev Neurother. 2007;7:769–781.
13.
CzuczwarSJPatsalosPM. The new generation of GABA enhancers: Potential in the treatment of epilepsy. CNS Drugs. 2001;15:339–350.
14.
StahlS.Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as α2δ ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004;65:460–461.
15.
StahlS.Mechanism of action of α2δ ligands: Voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiatry. 2004;65:1033–1034.
Pfizer Inc. Prescribing information—LYRICA (pregabalin). New York (NY): Pfizer; 2010.
18.
BrockbraderHNRadulovicLLPosvarELClinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Psychopharmacol. 2010;50:941–950.
19.
FeltnerDECrockattJGDubovskySJA randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240–249.
20.
PandeACCrockattJGFeltnerDEPregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry. 2003;160:533–540.
21.
RickelsKPollackMHFeltnerDEPregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022–1030.
22.
PohlRBFeltnerDEFieveRREfficacy of pregabalin in the treatment of generalized anxiety disorder: Double-blind, plaebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151–158.
23.
MontgomerySATobiasKZornbergGLEfficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67:771–782.
24.
MontgomerySAChatamraKPauerLEfficacy and safety of pregabalin in elderly people with generalized anxiety disorder. Br J Psychiatry. 2008;193:389–394.
25.
KasperSHermanBNivoliGEfficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: Results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009;24:87–96.
26.
FeltnerDWittchenH-UKavoussiRLong-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23:18–28.
27.
HidalgoRBTuplerLADavidsonJRT. An effect-size analysis of pharmacological treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21:864–872.
28.
HamiltonM.The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–55.
29.
HedgesLV. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Stat. 1981;6:107–128.
30.
CohenJ.Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
31.
KobakKAReynoldsWMGreistJH. Development and validation of a computer-administered version of the Hamilton Anxiety Scale. Psychol Assess. 1993;5:487–494.
KirschISapirsteinG.Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prev Treat. 1998;2:Article2a.
34.
KirschIDeaconBJHuedo-MedinaTBInitial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
35.
FountoulakisKNMöllerH-J.Efficacy of antidepressants: A re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol. 2010;27:1–8.
36.
HorderJMatthewsPWaldmannR.Placebo, Prozac and PLoS: Significant lessons for psychopharmacology. J Psychopharmacol. 2010 June 22. Epub ahead of print.
37.
MitteK.Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: A comparison with pharmacotherapy. Psychol Bull. 2005;131:785–795.
